vs
Side-by-side financial comparison of CHEMED CORP (CHE) and Enhabit, Inc. (EHAB). Click either name above to swap in a different company.
CHEMED CORP is the larger business by last-quarter revenue ($420.0M vs $270.4M, roughly 1.6× Enhabit, Inc.). CHEMED CORP runs the higher net margin — 15.8% vs -14.3%, a 30.1% gap on every dollar of revenue. On growth, Enhabit, Inc. posted the faster year-over-year revenue change (4.7% vs 3.1%). Over the past eight quarters, CHEMED CORP's revenue compounded faster (5.9% CAGR vs 1.5%).
LG Chem Ltd., often referred to as LG Chemical, is the largest Korean chemical company and is headquartered in Seoul, South Korea. It was the 9th largest chemical company in the world by sales in 2021. It was first established as the Lucky Chemical Industrial Corporation, which manufactured cosmetics. It is now solely a business-to-business company.
Enhabit, Inc., is a Dallas, Texas-based provider of home health and hospice services. The company operates 255 home health and 110 hospice locations in 34 states with a concentration in Texas, Alabama, Florida, Georgia, Oklahoma and Mississippi. Enhabit is the fourth-largest provider of home health services in the United States and is a leading provider of hospice services. The company was formed in 2022 when Encompass Health spun off its home health and hospice business.
CHE vs EHAB — Head-to-Head
Income Statement — Q1 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $420.0M | $270.4M |
| Net Profit | $66.3M | $-38.7M |
| Gross Margin | — | — |
| Operating Margin | 20.1% | -12.3% |
| Net Margin | 15.8% | -14.3% |
| Revenue YoY | 3.1% | 4.7% |
| Net Profit YoY | -7.6% | 15.9% |
| EPS (diluted) | — | $-0.76 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $420.0M | — | ||
| Q4 25 | $639.3M | $270.4M | ||
| Q3 25 | $624.9M | $263.6M | ||
| Q2 25 | $618.8M | $266.1M | ||
| Q1 25 | $646.9M | $259.9M | ||
| Q4 24 | $411.0M | $258.2M | ||
| Q3 24 | $391.4M | $253.6M | ||
| Q2 24 | $374.6M | $260.6M |
| Q1 26 | $66.3M | — | ||
| Q4 25 | $76.8M | $-38.7M | ||
| Q3 25 | $64.2M | $11.1M | ||
| Q2 25 | $52.5M | $5.2M | ||
| Q1 25 | $71.8M | $17.8M | ||
| Q4 24 | $90.3M | $-46.0M | ||
| Q3 24 | $75.8M | $-110.2M | ||
| Q2 24 | $70.9M | $-200.0K |
| Q1 26 | — | — | ||
| Q4 25 | 35.2% | — | ||
| Q3 25 | 31.5% | — | ||
| Q2 25 | 29.8% | — | ||
| Q1 25 | 33.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | -1.2% | — | ||
| Q2 24 | -4.1% | — |
| Q1 26 | 20.1% | — | ||
| Q4 25 | 15.7% | -12.3% | ||
| Q3 25 | 12.0% | 6.4% | ||
| Q2 25 | 11.0% | 6.3% | ||
| Q1 25 | 14.6% | 6.1% | ||
| Q4 24 | 27.7% | -16.0% | ||
| Q3 24 | 23.5% | -38.6% | ||
| Q2 24 | 23.5% | 4.3% |
| Q1 26 | 15.8% | — | ||
| Q4 25 | 12.0% | -14.3% | ||
| Q3 25 | 10.3% | 4.2% | ||
| Q2 25 | 8.5% | 2.0% | ||
| Q1 25 | 11.1% | 6.8% | ||
| Q4 24 | 22.0% | -17.8% | ||
| Q3 24 | 19.4% | -43.5% | ||
| Q2 24 | 18.9% | -0.1% |
| Q1 26 | — | — | ||
| Q4 25 | $5.45 | $-0.76 | ||
| Q3 25 | $4.46 | $0.22 | ||
| Q2 25 | $3.57 | $0.10 | ||
| Q1 25 | $4.86 | $0.35 | ||
| Q4 24 | $6.00 | $-0.92 | ||
| Q3 24 | $5.00 | $-2.20 | ||
| Q2 24 | $4.65 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $16.9M | $43.6M |
| Total DebtLower is stronger | $91.2M | $426.0M |
| Stockholders' EquityBook value | $848.0M | $534.0M |
| Total Assets | $1.5B | $1.2B |
| Debt / EquityLower = less leverage | 0.11× | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $16.9M | — | ||
| Q4 25 | $74.5M | $43.6M | ||
| Q3 25 | $129.8M | $56.9M | ||
| Q2 25 | $249.9M | $37.1M | ||
| Q1 25 | $173.9M | $39.5M | ||
| Q4 24 | $178.3M | $28.4M | ||
| Q3 24 | $238.5M | $45.7M | ||
| Q2 24 | $222.9M | $28.5M |
| Q1 26 | $91.2M | — | ||
| Q4 25 | — | $426.0M | ||
| Q3 25 | — | $441.5M | ||
| Q2 25 | — | $456.9M | ||
| Q1 25 | — | $467.3M | ||
| Q4 24 | — | $492.6M | ||
| Q3 24 | — | $502.9M | ||
| Q2 24 | — | $512.7M |
| Q1 26 | $848.0M | — | ||
| Q4 25 | $979.4M | $534.0M | ||
| Q3 25 | $1.1B | $566.8M | ||
| Q2 25 | $1.2B | $552.4M | ||
| Q1 25 | $1.2B | $543.2M | ||
| Q4 24 | $1.1B | $523.5M | ||
| Q3 24 | $1.2B | $566.1M | ||
| Q2 24 | $1.2B | $674.3M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $1.2B | ||
| Q3 25 | $1.6B | $1.2B | ||
| Q2 25 | $1.7B | $1.2B | ||
| Q1 25 | $1.7B | $1.2B | ||
| Q4 24 | $1.7B | $1.2B | ||
| Q3 24 | $1.8B | $1.3B | ||
| Q2 24 | $1.7B | $1.4B |
| Q1 26 | 0.11× | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.78× | ||
| Q2 25 | — | 0.83× | ||
| Q1 25 | — | 0.86× | ||
| Q4 24 | — | 0.94× | ||
| Q3 24 | — | 0.89× | ||
| Q2 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $88.2M | $4.4M |
| Free Cash FlowOCF − Capex | — | $3.3M |
| FCF MarginFCF / Revenue | — | 1.2% |
| Capex IntensityCapex / Revenue | 4.1% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.33× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $65.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $88.2M | — | ||
| Q4 25 | $133.5M | $4.4M | ||
| Q3 25 | $83.4M | $37.8M | ||
| Q2 25 | $138.6M | $10.6M | ||
| Q1 25 | $32.7M | $17.9M | ||
| Q4 24 | $164.9M | $-4.1M | ||
| Q3 24 | $90.5M | $28.4M | ||
| Q2 24 | $77.5M | $9.6M |
| Q1 26 | — | — | ||
| Q4 25 | $117.2M | $3.3M | ||
| Q3 25 | $66.0M | $36.2M | ||
| Q2 25 | $122.8M | $8.7M | ||
| Q1 25 | $19.5M | $17.6M | ||
| Q4 24 | $152.2M | $-4.7M | ||
| Q3 24 | $77.0M | $27.7M | ||
| Q2 24 | $66.5M | $8.9M |
| Q1 26 | — | — | ||
| Q4 25 | 18.3% | 1.2% | ||
| Q3 25 | 10.6% | 13.7% | ||
| Q2 25 | 19.8% | 3.3% | ||
| Q1 25 | 3.0% | 6.8% | ||
| Q4 24 | 37.0% | -1.8% | ||
| Q3 24 | 19.7% | 10.9% | ||
| Q2 24 | 17.7% | 3.4% |
| Q1 26 | 4.1% | — | ||
| Q4 25 | 2.6% | 0.4% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 2.6% | 0.7% | ||
| Q1 25 | 2.1% | 0.1% | ||
| Q4 24 | 3.1% | 0.2% | ||
| Q3 24 | 3.5% | 0.3% | ||
| Q2 24 | 3.0% | 0.3% |
| Q1 26 | 1.33× | — | ||
| Q4 25 | 1.74× | — | ||
| Q3 25 | 1.30× | 3.41× | ||
| Q2 25 | 2.64× | 2.04× | ||
| Q1 25 | 0.46× | 1.01× | ||
| Q4 24 | 1.83× | — | ||
| Q3 24 | 1.19× | — | ||
| Q2 24 | 1.09× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHE
| Homecare | $371.1M | 88% |
| Inpatient | $35.9M | 9% |
| Other | $13.0M | 3% |
EHAB
| Third Party Payor Medicare | $111.6M | 41% |
| Third Party Payor Medicare Advantage | $67.5M | 25% |
| Hospice Segment | $63.6M | 24% |
| Third Party Payor Managed Care | $24.9M | 9% |
| Third Party Payor Medicaid | $1.7M | 1% |
